On the basis of the first-generation recombinant protein COVID-19 vaccine, the R&D team conducted a comprehensive analysis and evaluation of the immune escape ability and evolutionary laws of various mutant strains, and newly designed and developed the second-generation recombinant protein COVID-19 vaccine.
Preclinical effectiveness studies and preliminary human trials have shown that the second-generation vaccine has broad-spectrum protection potential against multiple variant strains, and is currently the only second-generation vaccine approved for emergency use.
After immunization, it can induce the body to produce targeted neutralizing antibodies, thereby blocking the combination of the virus and the recipient cells and exerting a protective effect.
http://www.sinopharm.com/s/1223-4126-39973.html
Preclinical effectiveness studies and preliminary human trials have shown that the second-generation vaccine has broad-spectrum protection potential against multiple variant strains, and is currently the only second-generation vaccine approved for emergency use.
After immunization, it can induce the body to produce targeted neutralizing antibodies, thereby blocking the combination of the virus and the recipient cells and exerting a protective effect.
http://www.sinopharm.com/s/1223-4126-39973.html